Allogene Therapeutics
Kevin H. has an extensive work history in statistical programming. Kevin started their career as a Statistical Programmer at Facet Biotech in 2003, where they worked until 2009. Kevin then joined Medivation as a Senior Manager, progressing to the role of Sr. Statistical Programming Manager. In 2017, they transitioned to BeiGene as an Associate Director and later became the Director of Statistical Programming. In 2022, Kevin joined Allogene Therapeutics as the Director of Statistical Programming and Infrastructure and was subsequently promoted to Head of Statistical Programming and Infrastructure in 2023. Kevin has experience overseeing global statistical programming projects and has worked on the development of various drugs throughout their career.
Kevin H. has a Master of Business Administration (M.B.A.) degree in Finance, General from Michigan State University. Kevin also holds a Master's Degree in Computer Engineering from Santa Clara University. The duration or specific years of completion for each degree are not mentioned.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.